Package Leaflet: Information for the User
Cisatracurio Accordpharma 5 mg/ml solution for injection and infusion EFG
Read all of this leaflet carefully before you start using this medicine.
Contents of the pack
Cisatracurio Accordpharma contains the active substance cisatracurium besylate, which belongs to a group of medicines called muscle relaxants.
Cisatracurio is used:
Ask your doctor if you need more information about this medicine.
Do not use Cisatracurio Accordpharma:
Do not use Cisatracurio Accordpharma if any of the above applies to you. If you are not sure, talk to your doctor, nurse or pharmacist before using Cisatracurio Accordpharma.
Be especially careful with Cisatracurio Accordpharma:
Talk to your doctor, nurse or pharmacist before using this medicine:
If you are not sure if any of the above applies to you, talk to your doctor, nurse or pharmacist before you are given Cisatracurio Accordpharma.
Other medicines and Cisatracurio Accordpharma
Tell your doctor if you are using, have recently used or might use any other medicines.
In particular, tell your doctor if you are taking any of the following medicines:
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
A side effect of cisatracurium on the breast-fed baby cannot be excluded; however, it is not expected to occur if breast-feeding is resumed after the effects of the substance have disappeared. Cisatracurium is rapidly eliminated from the body. Women should not breast-feed for 3 hours after the end of treatment.
Driving and using machines
If you are going to be in hospital for only one day, your doctor will tell you how long you should wait before leaving the hospital or driving. It may be dangerous to drive soon after surgery.
How the injection is given
Never try to give yourself this medicine. It should always be given by a person qualified to do so.
Cisatracurio Accordpharma can be given:
Your doctor will decide on the dose and duration of treatment that is right for you.
This will depend on:
This medicine should not be given to children under 1 month of age.
If you are given too much Cisatracurio Accordpharma
Cisatracurio Accordpharma will always be given under properly controlled conditions. However, if you think you have been given too much medicine, tell your doctor or nurse immediately.
If you have any other questions about the use of this medicine, ask your doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you experience any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet.
Allergic reactions (affect less than 1 in 10,000 patients)
If you have had an allergic reaction, tell your doctor or nurse immediately. The signs may include:
Talk to your doctor, nurse or pharmacist if you notice any of the following:
Common side effects (affect less than 1 in 10 patients)
Uncommon side effects (affect less than 1 in 100 patients)
Rare side effects (affect less than 1 in 10,000 patients)
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist or nurse, even if they are not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Agency's website: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and vial after “EXP”. The expiry date is the last day of the month shown.
Store in a refrigerator (between 2°C and 8°C). Do not freeze.
Store in the original packaging to protect from light.
If diluted, store the infusion solution between 2°C and 8°C and use within 24 hours. Any unused infusion solution should be discarded after 24 hours of preparation.
Medicines should not be disposed of via wastewater or household waste. Your doctor or nurse will dispose of any unused medicine. This will help protect the environment.
What Cisatracurio Accordpharma contains
1 ml of solution for injection or infusion contains 6.70 mg of cisatracurium besylate, equivalent to 5 mg of cisatracurium.
1 vial of 30 ml of solution for injection or infusion contains 201 mg of cisatracurium besylate, equivalent to 150 mg of cisatracurium.
The other ingredients are benzenesulfonic acid and water for injections.
Appearance and packaging
Cisatracurio Accordpharma 5 mg/ml solution for injection and infusion is a colourless to light yellow or light yellow-green solution, practically free from visible particles, with a pH of 3.0-5.0, in a box containing one or five glass vials of 30 ml. Each 30 ml vial contains 150 mg of cisatracurium.
Not all pack sizes may be marketed.
Marketing authorisation holder:
Accord Healthcare S.L.U.
World Trade Center. Moll de Barcelona, s/n,
Edifici Est, 6ª planta.
08039, Barcelona
Spain
Manufacturer:
B Braun Medical, S.A.
Ronda de Los Olivares, parcela 11.
Pol. Ind. Los Olivares 23009 Jaén
Spain
This medicine is authorised in the Member States of the European Economic Area under the following names:
Spain: Cisatracurio Accordpharma 5 mg/ml solution for injection and infusion EFG.
Portugal: Cisatracúrio Combino 2 mg/ml Solução injectável/perfusão MG
Italy: Cisatracurio Combino Pharm 2 mg/ml Soluzione iniettabile/infusione
This leaflet was approved inDecember 2023
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.es/